Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 21 citing articles:

Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
Xiao‐Qing Guan, Yang Yang, Lanying Du
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 422-439
Open Access | Times Cited: 19
A microneedle-based delivery system for broad-protection seasonal influenza A DNA nanovaccines
Liangliang Wang, Li Yang, Feng Zhang, et al.
Cell Reports Physical Science (2023) Vol. 4, Iss. 6, pp. 101430-101430
Open Access | Times Cited: 13
Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2
Michael D. Grant, Kirsten Bentley, Ceri A. Fielding, et al.
JCI Insight (2023) Vol. 8, Iss. 15
Open Access | Times Cited: 13
Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
James A. Williams, Marco Biancucci, Laura N. Lessen, et al.
Science Advances (2023) Vol. 9, Iss. 23
Open Access | Times Cited: 13
Towards developing multistrain PEDV vaccines: Integrating basic concepts and SARS-CoV-2 pan-sarbecovirus strategies
Mario Fragoso-Saavedra, Qiang Liu
Virology (2025) Vol. 604, pp. 110412-110412
Closed Access
Host–Pathogen Interaction Interface: Promising Candidate Targets for Vaccine-Induced Protective and Memory Immune Responses
Gloria Guillermina Guerrero Manríquez, Vicente Madrid‐Marina, Aurora Martínez-Romero, et al.
Vaccines (2025) Vol. 13, Iss. 4, pp. 418-418
Open Access
Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
Yanfang Zhang, Xinrui Kang, Sheng Liu, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 9, pp. e1011659-e1011659
Open Access | Times Cited: 8
Global domination of the recently VoI-classified 'JN.1′ outcompeting other variants – Comparing the vaccines’ efficacy
Ranjan K. Mohapatra, Venkataramana Kandi, Abhay Gaidhane, et al.
Clinical Infection in Practice (2024) Vol. 22, pp. 100358-100358
Open Access | Times Cited: 2
A novel mutation-proof, next-generation vaccine to fight against upcoming SARS-CoV-2 variants and subvariants, designed through AI enabled approaches and tools, along with the machine learning based immune simulation: A vaccine breakthrough
Manojit Bhattacharya, Abdulrahman Alshammari, Metab Alharbi, et al.
International Journal of Biological Macromolecules (2023) Vol. 242, pp. 124893-124893
Open Access | Times Cited: 5
The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection
Arjan Bains, Wenyan Guan, Patricia J. LiWang
Viruses (2023) Vol. 15, Iss. 9, pp. 1901-1901
Open Access | Times Cited: 5
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial
Nawal Al Kaabi, Yun Yang, Yu Liang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Mosaic Receptor Binding Domain Nanoparticles: Towards Fourth-Generation Vaccination
Vivek P. Chavda, Vasso Apostolopoulos
Nanomedicine (2023) Vol. 18, Iss. 19, pp. 1223-1226
Closed Access | Times Cited: 4
Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS‐CoV‐2 neutralization
Veronica Aparecida de Lima, João Paulo Silva Nunes, Daniela Santoro Rosa, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 7
Open Access | Times Cited: 1
A Unique mRNA Vaccine Elicits Protective Efficacy against the SARS-CoV-2 Omicron Variant and SARS-CoV
Xiao‐Qing Guan, Abhishek Kumar Verma, Gang Wang, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 605-605
Open Access | Times Cited: 1
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium
Laura Marcos-Villar, Beatriz Perdiguero, María López‐Bravo, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Hybrid immunity elicits potent cross-variant ADCC against SARS-CoV-2 through a combination of anti-S1 and S2 antibodies
Michael D. Grant, Kirsten Bentley, Ceri A. Fielding, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Proanthocyanidins-based adjuvant for enhanced immune responses of SARS-CoV-2 subunit vaccine
Yun Sun, Zibo Han, Lifang Du, et al.
Journal of Drug Delivery Science and Technology (2024), pp. 106185-106185
Closed Access
Fluoroamphiphiles for enhancing immune response of subunit vaccine against SARS-CoV-2
Yuan Li, Ziyao Kang, Xuefeng Zhang, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2024) Vol. 204, pp. 114528-114528
Closed Access
Impact of mutations on the plant-based production of recombinant SARS-CoV-2 RBDs
Valentina Ruocco, Ulrike Vavra, Julia König-Beihammer, et al.
Frontiers in Plant Science (2023) Vol. 14
Open Access | Times Cited: 1
Co-Mutations and Possible Variation Tendency of the Spike RBD and Membrane Protein in SARS-CoV-2 by Machine Learning
Qiushi Ye, He Wang, Fanding Xu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4662-4662
Open Access
Structural and Computational Design of a SARS-2 Spike Antigen with Increased Receptor Binding Domain Exposure and Improved Immunogenicity
James A. Williams, Marco Biancucci, Laura N. Lessen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Page 1

Scroll to top